Work

Supplementary Figure S4 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer

Year: 2025

Type: supplementary-materials

Abstract: Supplementary Figure S4 shows change in ocular pressure over time with rebastinib plus antitubulin therapy. (p value is derived from the Wilcoxon signed rank test comparing changes in ocular pressure over time within a rebastinib dose level. Paired samples for 50 mg dose = 6, paired samples for 100 mg dose = 10). Abbreviations: C5, Cycle five; C9, Cycle nine.

DOI: 10.1158/1078-0432.28227614

Authors: Jesus D. Anampa, Daniel L. Flynn, Cynthia Leary, Sun Oh, Xiaonan Xue, Maja H. Oktay, John S. Condeelis, Joseph A. Sparano

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4406541142

Cites:

Cited by:

Related to: 10